Total Payments
$46,985
2024 Payments
$9,717
Companies
93
Transactions
2,101
Medicare Patients
1,497
Medicare Billing
$455,170
Payment Breakdown by Category
Food & Beverage$38,035 (81.0%)
Consulting$6,790 (14.5%)
Other$1,147 (2.4%)
Education$1,013 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $38,035 | 2,062 | 81.0% |
| Consulting Fee | $6,790 | 4 | 14.5% |
| Long term medical supply or device loan | $1,147 | 12 | 2.4% |
| Education | $1,013 | 23 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $5,485 | 68 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,596 | 141 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $3,284 | 35 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,466 | 117 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,159 | 210 | $0 (2024) |
| Incyte Corporation | $1,975 | 94 | $0 (2024) |
| Celgene Corporation | $1,945 | 134 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,809 | 89 | $0 (2024) |
| Amgen Inc. | $1,749 | 84 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $1,501 | 92 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,717 | 398 | Novartis Pharmaceuticals Corporation ($1,630) |
| 2023 | $9,030 | 359 | Eisai Inc. ($2,225) |
| 2022 | $7,666 | 298 | EISAI INC. ($2,110) |
| 2021 | $6,807 | 227 | Bayer HealthCare Pharmaceuticals Inc. ($2,837) |
| 2020 | $4,309 | 246 | AstraZeneca Pharmaceuticals LP ($375.56) |
| 2019 | $4,777 | 289 | Genentech USA, Inc. ($503.38) |
| 2018 | $3,370 | 218 | E.R. Squibb & Sons, L.L.C. ($312.10) |
| 2017 | $1,309 | 66 | Pharmacyclics LLC, An AbbVie Company ($207.09) |
All Payment Transactions
2,101 individual payment records from CMS Open Payments — Page 1 of 85
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | DARZALEX (Drug), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: Oncology | ||||||
| 12/19/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $31.20 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/17/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.98 | General |
| 12/12/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $20.55 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $0.99 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.55 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.05 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.30 | General |
| Category: Hematology/Oncology | ||||||
| 11/26/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.60 | General |
| Category: Hematology/Oncology | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $32.94 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.31 | General |
| Category: Hematology | ||||||
| 11/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.06 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 321 | 2,715 | $233,246 | $95,698 |
| 2022 | 15 | 357 | 2,851 | $249,959 | $107,043 |
| 2021 | 14 | 422 | 5,851 | $311,310 | $126,803 |
| 2020 | 16 | 397 | 5,371 | $322,695 | $125,626 |
Total Patients
1,497
Total Services
16,788
Medicare Billing
$455,170
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 293 | $73,250 | $29,499 | 40.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 163 | $48,900 | $22,495 | 46.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 167 | $48,430 | $19,669 | 40.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 95 | $21,375 | $9,471 | 44.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 91 | $11,830 | $5,385 | 45.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 17 | 122 | $9,150 | $3,202 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $5,250 | $2,284 | 43.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $4,950 | $2,044 | 41.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 23 | $2,875 | $1,497 | 52.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 15 | 1,020 | $5,100 | $99.99 | 2.0% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 12 | 712 | $2,136 | $53.97 | 2.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 177 | $53,100 | $27,244 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 228 | $57,000 | $23,711 | 41.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 23 | 184 | $53,360 | $22,915 | 42.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 99 | $22,275 | $8,559 | 38.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 11 | 36 | $14,400 | $6,596 | 45.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 13 | 80 | $10,400 | $4,970 | 47.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $8,250 | $4,194 | 50.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 17 | 102 | $7,650 | $2,828 | 37.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $5,280 | $2,513 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 27 | $3,375 | $1,466 | 43.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 11 | 49 | $4,410 | $1,280 | 29.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 15 | 40 | $2,200 | $585.48 | 26.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 14 | 1,001 | $5,000 | $96.80 | 1.9% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2022 | 13 | 753 | $2,704 | $50.63 | 1.9% |
About Dr. Derrick Su, MD
Dr. Derrick Su, MD is a Specialist healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2011. The National Provider Identifier (NPI) number assigned to this provider is 1740569789.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Derrick Su, MD has received a total of $46,985 in payments from pharmaceutical and medical device companies, with $9,717 received in 2024. These payments were reported across 2,101 transactions from 93 companies. The most common payment nature is "Food and Beverage" ($38,035).
As a Medicare-enrolled provider, Su has provided services to 1,497 Medicare beneficiaries, totaling 16,788 services with total Medicare billing of $455,170. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Fountain Valley, CA
- Active Since 08/09/2011
- Last Updated 05/15/2019
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1740569789
Products in Payments
- Lenvima (Drug) $5,334
- Vitrakvi (Drug) $2,750
- KISQALI (Drug) $1,755
- KEYTRUDA (Biological) $1,702
- OPDIVO (Biological) $1,584
- IMBRUVICA (Drug) $1,166
- JAKAFI (Drug) $1,020
- REBLOZYL (Biological) $914.93
- Imbruvica (Drug) $777.54
- LIBTAYO (Biological) $717.27
- LYNPARZA (Drug) $665.82
- MONJUVI (Drug) $657.52
- ULTOMIRIS (Biological) $591.85
- Pomalyst (Drug) $548.73
- VERZENIO (Drug) $500.62
- CABOMETYX (Drug) $469.89
- XPOVIO (Drug) $467.96
- IBRANCE (Drug) $462.00
- ADCETRIS (Biological) $459.27
- MEKINIST (Drug) $446.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Fountain Valley
Dr. Reginald Abraham, M D, M D
Specialist — Payments: $219,375
Specialist $219,375
Haresh Jhangiani, M.d, M.D
Specialist — Payments: $98,307
Specialist $98,307
Dr. Stephen Rakower, M.d, M.D
Specialist — Payments: $40,477
Specialist $40,477
Julie Thompson-Dobkin, Do, DO
Specialist — Payments: $23,931
Specialist $23,931
Dr. Quan Nguyen, M.d, M.D
Specialist — Payments: $17,885
Specialist $17,885
Anatol Podolsky, M.d, M.D
Specialist — Payments: $11,789
Specialist $11,789